Dianthus Therapeutics Valuation
| DNTH Stock | 20.27 0.50 2.41% |
At this time, the firm appears to be undervalued. Dianthus Therapeutics shows a prevailing Real Value of USD21.22 per share. The current price of the firm is USD20.27. Our model computes the value of Dianthus Therapeutics from reviewing the firm fundamentals such as Shares Outstanding of 29.6 M, operating margin of (13.77) %, and Current Valuation of 333.92 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Dianthus Therapeutics' valuation include:
Price Book 1.8193 | Enterprise Value 333.9 M | Enterprise Value Ebitda (7.35) | Price Sales 114.5601 | Trailing PE 2.8767 |
Undervalued
Today
Please note that Dianthus Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Dianthus Therapeutics is based on 3 months time horizon. Increasing Dianthus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dianthus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dianthus Stock. However, Dianthus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.27 | Real 21.22 | Target 24.0 | Hype 21.42 | Naive 16.72 |
The intrinsic value of Dianthus Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Dianthus Therapeutics' stock price.
Estimating the potential upside or downside of Dianthus Therapeutics helps investors to forecast how Dianthus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dianthus Therapeutics more accurately as focusing exclusively on Dianthus Therapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Dianthus Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Dianthus Therapeutics Cash |
|
Dianthus Valuation Trend
Dianthus Therapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both Dianthus Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Dianthus Therapeutics Total Value Analysis
Dianthus Therapeutics is currently anticipated to have valuation of 333.92 M with market capitalization of 614.73 M, debt of 585 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Dianthus Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
333.92 M | 614.73 M | 585 K |
Dianthus Therapeutics Investor Information
About 91.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.82. Some equities with similar Price to Book (P/B) outperform the market in the long run. Dianthus Therapeutics recorded earning per share (EPS) of 7.22. The entity had not issued any dividends in recent years. The firm had 1:16 split on the 12th of September 2023. Based on the key indicators related to Dianthus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Dianthus Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Dianthus Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Dianthus Therapeutics has an asset utilization ratio of 1.58 percent. This signifies that the Company is making USD0.0158 for each dollar of assets. An increasing asset utilization means that Dianthus Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Dianthus Therapeutics Ownership Allocation
The majority of Dianthus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dianthus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dianthus Therapeutics. Please pay attention to any change in the institutional holdings of Dianthus Therapeutics as this could imply that something significant has changed or is about to change at the company.Dianthus Therapeutics Profitability Analysis
The company reported the previous year's revenue of 2.83 M. Net Loss for the year was (43.55 M) with profit before overhead, payroll, taxes, and interest of 6.42 M.About Dianthus Therapeutics Valuation
An absolute valuation paradigm, as applied to Dianthus Stock, attempts to find the value of Dianthus Therapeutics based on its fundamental and basic technical indicators. By analyzing Dianthus Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Dianthus Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Dianthus Therapeutics. We calculate exposure to Dianthus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dianthus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.5 M | 2.6 M | |
| Pretax Profit Margin | (15.41) | (16.18) | |
| Operating Profit Margin | (17.05) | (17.90) | |
| Net Loss | (15.41) | (16.18) | |
| Gross Profit Margin | 0.87 | 0.92 |
Dianthus Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 5.2 M |
Dianthus Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Dianthus Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Dianthus we look at many different elements of the entity such as Dianthus's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Dianthus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Dianthus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Dianthus Therapeutics' worth.Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |